Xth Eurasian Hematology-Oncology Congress

http://www.ehog.net/

 

Xth Eurasian Hematology-Oncology Congress
M

Sequencing Agents in the Management of EGFR+ NSCLC: TKI Optimal Treatment Options as 1st and 2nd Line Treatment + TKI Resistance Mechanisms

By Xth Eurasian Hematology-Oncology Congress FEATURING Mustafa Erman
By Xth Eurasian Hematology-Oncology Congress FEATURING Mustafa Erman
110 views
November 12, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison
Lung
05:21

Management of ALK+ NSCLC Through First and Subsequent Lines of Thera…

Xth Eurasian Hematology-Oncology Congress

P. Yumuk

89 views
17:12

Management of ALK+ NSCLC Through 1st and Subsequent Lines of Therapy…

Xth Eurasian Hematology-Oncology Congress

P. Yumuk

170 views
20:50

Sequencing Agents in the Management of EGFR+ NSCLC: TKI Optimal Trea…

Xth Eurasian Hematology-Oncology Congress

M. Erman

110 views
08:26

Sequencing Agents in the Management of EGFR+ NSCLC: Optimal 1st and …

Xth Eurasian Hematology-Oncology Congress

M. Erman

206 views
05:02

Anti-PD-1 / Anti-PD-L1 as Standard 2nd Line Treatment Improved OS in…

Xth Eurasian Hematology-Oncology Congress

B. Uluc

121 views
05:57

1st, 2nd, 3rd Line & Maintenance IO Options in Locally Advanced NSCL…

Xth Eurasian Hematology-Oncology Congress

B. Uluc

181 views
14:46

Anti-PD-1 / Anti-PD-L1 in Newly Diagnosed Advanced NSCLC: Is Treatme…

Xth Eurasian Hematology-Oncology Congress

B. Uluc

288 views